Your browser doesn't support javascript.
loading
Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma.
Tenente, Inês M; Hayes, Madeline N; Ignatius, Myron S; McCarthy, Karin; Yohe, Marielle; Sindiri, Sivasish; Gryder, Berkley; Oliveira, Mariana L; Ramakrishnan, Ashwin; Tang, Qin; Chen, Eleanor Y; Petur Nielsen, G; Khan, Javed; Langenau, David M.
Afiliación
  • Tenente IM; Molecular Pathology, Cancer Center, and Regenerative Medicine, Massachusetts General Hospital, Boston, United States.
  • Hayes MN; Harvard Stem Cell Institute, Cambridge, United States.
  • Ignatius MS; GABBA Program, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal.
  • McCarthy K; Molecular Pathology, Cancer Center, and Regenerative Medicine, Massachusetts General Hospital, Boston, United States.
  • Yohe M; Harvard Stem Cell Institute, Cambridge, United States.
  • Sindiri S; Molecular Pathology, Cancer Center, and Regenerative Medicine, Massachusetts General Hospital, Boston, United States.
  • Gryder B; Harvard Stem Cell Institute, Cambridge, United States.
  • Oliveira ML; Molecular Medicine, Greehey Children's Cancer Research Institute, San Antonio, United States.
  • Ramakrishnan A; Molecular Pathology, Cancer Center, and Regenerative Medicine, Massachusetts General Hospital, Boston, United States.
  • Tang Q; Harvard Stem Cell Institute, Cambridge, United States.
  • Chen EY; Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, United States.
  • Petur Nielsen G; Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, United States.
  • Khan J; Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, United States.
  • Langenau DM; Molecular Pathology, Cancer Center, and Regenerative Medicine, Massachusetts General Hospital, Boston, United States.
Elife ; 62017 01 12.
Article en En | MEDLINE | ID: mdl-28080960
Rhabdomyosarcoma (RMS) is a pediatric malignacy of muscle with myogenic regulatory transcription factors MYOD and MYF5 being expressed in this disease. Consensus in the field has been that expression of these factors likely reflects the target cell of transformation rather than being required for continued tumor growth. Here, we used a transgenic zebrafish model to show that Myf5 is sufficient to confer tumor-propagating potential to RMS cells and caused tumors to initiate earlier and have higher penetrance. Analysis of human RMS revealed that MYF5 and MYOD are mutually-exclusively expressed and each is required for sustained tumor growth. ChIP-seq and mechanistic studies in human RMS uncovered that MYF5 and MYOD bind common DNA regulatory elements to alter transcription of genes that regulate muscle development and cell cycle progression. Our data support unappreciated and dominant oncogenic roles for MYF5 and MYOD convergence on common transcriptional targets to regulate human RMS growth.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Rabdomiosarcoma / Transcripción Genética / Proteína MioD / Factor 5 Regulador Miogénico Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Elife Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Rabdomiosarcoma / Transcripción Genética / Proteína MioD / Factor 5 Regulador Miogénico Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Elife Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos